Abbott's Xinlay To Face Advisory Committee Review Sept. 13; Celgene's Revlimid On Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Arranon (nelarabine) for acute lymphoblastic leukemia will also be part of the Sept. 13-14 meeting of FDA's Oncologic Drugs Advisory Committee.